[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Myocarditis, don't bother to report", "description": "TGA to stop reporting myocarditis\n\nTo donate to the work of campbellteaching around the world,\n\nhttps://www.paypal.com/donate/?hosted_button_id=XS59XPZ527YFL\n\nMyocarditis is reported in around 2 in every 100,000 of those who receive Spikevax (Moderna).\n\nAs reporting rates of myocarditis and pericarditis following vaccination are very stable, \n\nwe will not include this section in future COVID-19 vaccine safety reports. \n\nHowever, we continue to monitor and review these adverse effects and will communicate any updated safety advice if needed.\n\nhttps://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-safety-report-13-07-2023#myocarditis-and-pericarditis-after-covid19-vaccination\n\nhttps://www.outkick.com/silent-killer-australia-to-stop-reporting-on-myocarditis-cases-related-to-covid-vaccine/\n\nPrimary course recommendations\n\nCOVID-19 vaccination is recommended for all people aged 5 years or older to protect against COVID-19. \n\nFor most people, a primary vaccination course consists of 2 doses.\n\nAdverse reactions, TGA data\n\nOne adverse event report per 490 doses given, 0.2039%\n\nIn Western Australia\n\nhttps://www.health.wa.gov.au/~/media/Corp/Documents/Health-for/Immunisation/Western-Australia-Vaccine-Safety-Surveillance-Annual-Report-2021.pdf\n\n0.241%\n\n10,428 adverse events (97%) occurred after a COVID-19 vaccine\n\n21 times more common than \u2018conventional\u2019 vaccines\n\nSwiss data\n\nMyocardial Injury after COVID-19 mRNA-1273 Booster Vaccination \n\nhttps://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2978\n\nmRNA-1273 vaccine-associated myocardial injury was adjudicated in 22 participants (2.8%).\n\n(N = 777 per group)\n\nOne in 35 recipients (2.8%) had vaccine-associated myocardial injury\n\nMatched controls, elevated high-sensitivity cardiac troponin T concentration\n\nSignificantly higher in post vaccination group p less than 0.001\n\nThai study\n\nCardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414075/\n\nAfter BNT162b2, 2nd dose, Thai adolescents, aged 13\u201318 years, \nn = 314\n\nSeven participants (2.33%) exhibited at least one elevated cardiac biomarker\n\nMyopericarditis was confirmed in one patient after vaccination. \n\nTwo patients had suspected pericarditis\n\nFour patients had suspected subclinical myocarditis\n\nHence, adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects.\n\nIsraeli study\n\nA prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons\n\nhttps://pubmed.ncbi.nlm.nih.gov/36097844/\n\nIncidence of myocardial injury after fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech)\n\nN = 324\n\nReported vaccine-related adverse reactions\n\nChest pain in 12 (3.7%)\n\nPalpitations in 7 (2.16%)\n\nVaccine-related myocardial injury in two (0.62%)\nhttps://www.gov.uk/government/publications/myocarditis-and-pericarditis-after-covid-19-vaccination/myocarditis-and-pericarditis-after-covid-19-vaccination-guidance-for-healthcare-professionals\n\nPost-COVID-19 vaccination\n\nAs of 23 November 2022, \n\nfollowing  Pfizer/BioNTech\n\n851 reports of myocarditis and \n\n579 reports of pericarditis\n\nTotal of 1,430\n\nFollowing Moderna vaccine\n251 reports of myocarditis\n\n149 reports of pericarditis\n\nTotal of 1,530\n\nAs of 23 November 2022, \n\nmyocarditis following monovalent Pfizer/BioNTech was 10 reports per million doses; \n\nIf there is a suspicion of myocarditis or pericarditis, initial investigations should be:\n\n12 lead electrocardiogram (ECG)\n\ninflammatory blood markers (C-reactive protein (CRP), full blood count (FBC) and erythrocyte sedimentation rate (ESR)\n\nTroponin\n\nIf there is no evidence of ongoing myocarditis, vaccination may be considered with the Pfizer/BioNTech (Cominarty) vaccine from 12 weeks after their last dose if further doses are due. \n\nIf the individual feels well after receiving their COVID-19 vaccination, then there is no need to pre-emptively restrict physical activity post vaccination and individuals can continue with their pre-existing level of physical activity.", "link": "https://www.youtube.com/watch?v=uVd6IonyI0Y", "date_published": "2023-08-23T19:01:17.706012+00:00", "persistent": false, "dead": false, "artist": null, "album": null, "user": null, "language": "en-UK", "thumbnail": "https://i2.ytimg.com/vi/uVd6IonyI0Y/hqdefault.jpg"}]